| 12064437 |
Methods for treating systemic lupus erythematosus and the use of biomarkers as a predictor of clinical sensitivity to therapies |
Shaojun Tang |
2024-08-20 |
|
| 11660302 |
3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
Lei Wu, Ying Ye |
2023-05-30 |
|
| 11524950 |
Treatment of immune-related and inflammatory diseases |
Ying Ye, Donna J. Sutherland, Rajesh Chopra, Anita Gandhi |
2022-12-13 |
|
| 11357775 |
Combination therapies comprising apremilast and Tyk2 inhibitors |
Robert Plenge, Mary Adams, Lisa Beebe, Gilles Buchwalter, Tiffany Carr +1 more |
2022-06-14 |
|
| 11260046 |
(+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
George W. Muller, Hon-Wah Man, Chuansheng Ge |
2022-03-01 |
$700,250,000 |
| 11040024 |
Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
George W. Muller, Hon-Wah Man, Chuansheng Ge |
2021-06-22 |
$251,097,000 |
| 10980812 |
3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
Lei Wu, Ying Ye |
2021-04-20 |
|
| 10919883 |
Treatment of immune-related and inflammatory diseases |
Rajesh Chopra, Anita Gandhi |
2021-02-16 |
|
| 10751414 |
Methods of treating psoriasis using PD-1 binding antibodies |
Henry Hin Lee Chan, Eun Mi Hur, Roli Khattri, Monica Wai Ling Leung, Garth E. Ringheim |
2020-08-25 |
|
| 10610516 |
Methods of using (+)- 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1, 3-dione |
George W. Muller, Hon-Wah Man, Chuansheng Ge |
2020-04-07 |
$340,870,000 |
| 10596179 |
3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
Lei Wu, Ying Ye |
2020-03-24 |
|
| 10245266 |
3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus |
Lei Wu, Ying Ye |
2019-04-02 |
$268,678,000 |
| 10092542 |
Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
George W. Muller, Hon-Wah Man, Chuansheng Ge |
2018-10-09 |
$70,853,000 |
| 10047151 |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
Antonia Lopez-Girona, Anita Gandhi, Derek Mendy, Thomas O. Daniel |
2018-08-14 |
$149,275,000 |
| 10018637 |
Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilast |
Matthew William Burnell Trotter |
2018-07-10 |
|
| 9857359 |
Methods for determining drug efficacy using cereblon-associated proteins |
Rajesh Chopra, Antonia Lopez-Girona, Laura Corral, Maria Yinglin Wang, Pilgrim Jackson |
2018-01-02 |
$545,291,000 |
| 9724330 |
Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
George W. Muller, Hon-Wah Man, Chuansheng Ge |
2017-08-08 |
$177,077,000 |
| 9487519 |
5,6-Dialkyl-7-aminotriazolopyrimidines, their preparation and their use for controlling harmful fungi, and compositions comprising these compounds |
Jordi Blasco, Carsten Blettner, Bernd Muller, Markus Gewehr, Wassilios Grammenos +10 more |
2016-11-08 |
|
| 9480676 |
Use of PDE4 inhibitors and combinations thereof for the treatment of cystic fibrosis |
Shimon Korish |
2016-11-01 |
$539,967,000 |
| 9433606 |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
George W. Muller, Hon-Wah Man, Chuansheng Ge, Jean Xu |
2016-09-06 |
$191,258,000 |
| 9387195 |
Methods for treating diseases using isoindoline compounds |
Sai Shankar |
2016-07-12 |
$530,742,000 |
| 9365640 |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
Antonia Lopez-Girona, Anita Gandhi, Derek Mendy, Thomas O. Daniel |
2016-06-14 |
$177,508,000 |
| 9283207 |
Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
George W. Muller, Hon-Wah Man, Chuansheng Ge |
2016-03-15 |
$244,202,000 |
| 9272035 |
Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases |
Anita Gandhi, Lori Capone |
2016-03-01 |
$515,379,000 |
| 9018243 |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
George W. Muller, Hon-Wah Man, Chuansheng Ge, Jean Xu |
2015-04-28 |
$460,610,000 |
